Abbott’s FreeStyle Libre 3 standalone reader displays real-time glucose readings from a large, bright and easy-to-see screen. Credit: Abbott.

The US Food and Drug Administration (FDA) has approved a standalone reader device for Abbott’s FreeStyle Libre 3 integrated continuous glucose-monitoring system.

The new reader is a small handheld device and features a small sensor worn on the back of a person’s upper arm.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

It displays real-time glucose readings on a large and easy-to-see screen and allows users to manage their diabetes easily and quickly.

The FreeStyle Libre 3 reader is equipped with a rechargeable lithium-ion battery similar to those used in mobile phones. Its user manual provides detailed information regarding storage, charging and usage as well as the use of the associated USB cable and power adapter.

Abbott stated that users of the FreeStyle Libre 3 system will have the option to check their glucose levels using the existing smartphone apps.

See Also:

Abbott diabetes care business senior vice-president Jared Watkin said: “Our customers all over the world consistently tell us how our FreeStyle Libre technology has made an enormous, positive impact on their health and quality of life – they spend less time worrying and more time living.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

“The FreeStyle Libre 3 reader provides more choice to people living with diabetes to have access to lifesaving technology that is smaller and easier to use and comes without the high-cost burdens of other systems.”

The company aims to get the FreeStyle Libre 3 system covered under the Medicare scheme to enable patients to get reimbursement.

Last month, the US FDA approved the company’s Epic Max stented tissue valve for the treatment of aortic valve disease.